Biotech Values

[Mufaso]

AKRO- Shares up approx 35% pre market but not yet back to Oct 2023 levels when the stock reported 36 week data for its efruxifermin FGF21 NASH compound . The new data is at 96 weeks and has really impressive fibrosis improvement.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%)

50mg (36%, p<0.01) and 28mg (31%, p<0.01) EFX groups demonstrated ≥2 stage improvement in fibrosis[color=red][/color] without worsening of MASH, more than 10-fold the placebo rate (3%)

EFX-treated patients experienced statistically significant improvements on nearly all histological endpoints by ITT analysis as well as the primary analysis of patients with week 96 biopsies

Investor webcast at 8:00 am ET Monday, March 4, 2024